Incorporating the patient voice in sarcoma research : How can we assess health-related quality of life in this heterogeneous group of patients? a study protocol

Den Hollander, Dide and Fiore, Marco and Martin-Broto, Javier and Kasper, Bernd and Casado Herraez, Antonio and Kulis, Dagmara and Nixon, Ioanna and Sodergren, Samantha C. and Eichler, Martin and van Houdt, Winan J. and Desar, Ingrid M.E. and Ray-Coquard, Isabelle and Piccinin, Claire and Kosela-Paterczyk, Hanna and Miah, Aisha and Hentschel, Leopold and Singer, Susanne and Wilson, Roger and van der Graaf, Winette T.A. and Husson, Olga (2020) Incorporating the patient voice in sarcoma research : How can we assess health-related quality of life in this heterogeneous group of patients? a study protocol. Cancers, 13 (1). 1. ISSN 2072-6694 (https://doi.org/10.3390/cancers13010001)

[thumbnail of Holllander-etal-Cancers-2021-Incorporating-the-patient-voice-in-sarcoma-research]
Preview
Text. Filename: Holllander_etal_Cancers_2021_Incorporating_the_patient_voice_in_sarcoma_research.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo

Download (257kB)| Preview

Abstract

Sarcomas comprise 1% of adult tumors and are very heterogeneous. Long-lasting and cumulative treatment side-effects detract from the (progression-free) survival benefit of treatment. Therefore, it is important to assess treatment effectiveness in terms of patient-reported outcomes (PROs), including health-related quality of life (HRQoL) as well. However, questionnaires capturing the unique issues of sarcoma patients are currently lacking. Given the heterogeneity of the disease, the development of such an instrument may be challenging. The study aims to (1) develop an exhaustive list of all HRQoL issues relevant to sarcoma patients and determine content validity; (2) determine a strategy for HRQoL measurement in sarcoma patients. We will conduct an international, multicenter, mixed-methods study (registered at clinicaltrials.gov: NCT04071704) among bone or soft tissue sarcoma patients ≥18 years, using EORTC Quality of Life Group questionnaire development guidelines. First, an exhaustive list of HRQoL issues will be generated, derived from literature and patient (n = 154) and healthcare professional (HCP) interviews (n = 30). Subsequently, another group of sarcoma patients (n = 475) and HCPs (n = 30) will be asked to rate and prioritize the issues. Responses will be analyzed by priority, prevalence and range of responses for each item. The outcome will be a framework for tailored HRQoL measurement in sarcoma patients, taking into account sociodemographic and clinical variables.